CRISPR And CRISPR Associated Genes

CRISPR And CRISPR Associated Genes Market Outlook

The global CRISPR and CRISPR-associated genes market is projected to reach approximately USD 19.2 billion by 2035, growing at a Compound Annual Growth Rate (CAGR) of around 23.5% during the forecast period from 2025 to 2035. The market is primarily being driven by increasing investments in genomic research and a burgeoning demand for efficient gene-editing tools across various sectors, including agriculture and healthcare. Additionally, the rise in the prevalence of genetic disorders and the growing acceptance of personalized medicine are contributing significantly to market growth. Governments and private organizations are also heavily funding CRISPR research, further fueling advancements in this cutting-edge technology. Overall, the CRISPR market is becoming a cornerstone for modern biotechnology and holds vast potential for numerous applications across different verticals.

Growth Factor of the Market

The growth of the CRISPR and CRISPR-associated genes market can be attributed to several key factors. Firstly, the rising incidence of genetic disorders due to hereditary conditions has created a surge in demand for gene-editing techniques that can effectively alter or eliminate these disorders. Secondly, advancements in CRISPR technologies, such as improved delivery systems and more precise editing capabilities, have made these tools more accessible and effective for researchers and clinicians alike. Moreover, the agriculture sector is increasingly integrating CRISPR technology for developing genetically modified organisms (GMOs) that can withstand pests and diseases, ensuring food security. Furthermore, the growing interest in personalized medicine, where treatments are tailored to individual genetic profiles, is propelling the demand for CRISPR applications in healthcare. Lastly, an increase in strategic partnerships and collaborations between biotech companies and research institutions is further enhancing the market landscape, driving innovations that will likely open new avenues for CRISPR applications in various fields.

Key Highlights of the Market

• Significant growth anticipated due to rising investments in genomic research.
• Increasing prevalence of genetic disorders driving demand for gene-editing tools.
• Advancements in CRISPR technologies enhancing accessibility and precision.
• Integration of CRISPR in agricultural biotechnology for food security solutions.
• Strategic partnerships and collaborations fueling innovations in the market.

By Product Type

CRISPR Systems:

CRISPR systems are integral components of the gene-editing process and are projected to witness significant growth owing to their pivotal role in genome editing. These systems offer high specificity and efficiency in targeting specific genes, thereby facilitating precise modifications. The rising demand for customized genetic modifications in agriculture and healthcare sectors propels the growth of CRISPR systems. Moreover, advancements in the design and optimization of these systems are enhancing their applicability in various research and clinical settings, further sustaining their market growth. As a result, researchers are increasingly utilizing CRISPR systems to explore complex genetic functions and develop innovative therapeutic interventions.

CRISPR Kits:

CRISPR kits provide researchers with all essential components required for gene editing, making them a popular choice among academic institutions and research organizations. The convenience and comprehensiveness of these kits have significantly contributed to their widespread adoption. As researchers look for techniques that save time and enhance efficiency, the demand for CRISPR kits is on an upward trajectory. Manufacturers are continuously innovating to improve the ease of use of these kits, catering to a broader audience in genomic research. The availability of user-friendly kits, along with instructional materials, is also boosting the overall market, as it lowers the barrier to entry for researchers new to gene-editing technologies.

CRISPR Plasmids:

CRISPR plasmids are vital for delivering the CRISPR components effectively into target cells, which is essential for successful gene editing. These plasmids serve as vectors that carry the necessary instructions for the CRISPR system to create specific genetic modifications. With the increasing complexity of genetic engineering projects, the demand for high-quality CRISPR plasmids is growing. Additionally, advancements in synthetic biology and plasmid design are enabling the development of more efficient plasmids that can improve the overall success rates of gene-editing experiments. This growing demand underscores the importance of CRISPR plasmids in the broader context of genetic research and application.

CRISPR Libraries:

CRISPR libraries are comprehensive collections of CRISPR constructs designed for high-throughput screening and large-scale genetic studies. These libraries enable researchers to study the functions of multiple genes simultaneously, allowing for significant advancements in functional genomics and disease modeling. The increasing focus on understanding gene interactions and genetic pathways is propelling the demand for CRISPR libraries. Moreover, as researchers seek to uncover potential therapeutic targets for various diseases, CRISPR libraries are becoming indispensable tools in drug discovery and development. Continuous innovations in library design and composition are further enhancing their attractiveness for academic and commercial laboratories alike.

CRISPR Enzymes:

CRISPR enzymes, including Cas9, Cas12, Cas13, and others, are the driving forces behind the gene-editing capabilities of the CRISPR system. These enzymes are responsible for cutting DNA at specific locations, allowing for targeted modifications. The growing understanding of these enzymes' mechanisms and functions has led to the development of more advanced variants with improved specificity and reduced off-target effects. As research progresses, the demand for CRISPR enzymes is expected to rise, especially with their increasing application in various therapeutic areas, including oncology and genetic disorders. Overall, advancements in enzyme engineering and discovery are key trends contributing to the growth of this segment.

By Application

Genome Engineering:

Genome engineering is one of the most prominent applications of CRISPR technology, revolutionizing the way genetic modifications are performed. By enabling precise edits to the DNA sequence, CRISPR allows researchers to investigate gene functions and develop models for various diseases. This application has profound implications in medicine, as it can lead to the development of novel gene therapies for previously untreatable genetic disorders. Increasing investments and research efforts in genome engineering are driving its growth, with numerous clinical trials currently exploring CRISPR-based treatments. The desire for a deeper understanding of genetic pathways and their implications in health and disease is expected to sustain the expanding landscape of genome engineering applications.

Genetic Engineering:

Genetic engineering encompasses a broad spectrum of techniques used to manipulate an organism's genome, with CRISPR technology playing a central role. This application is witnessing significant growth due to the increasing need for genetically modified organisms (GMOs) in agriculture, as well as advances in research methodologies for improving crop yields and resistance to diseases. Additionally, the ability to create custom genetic modifications allows for the production of animals and plants with desirable traits, further propelling research in this area. As the agricultural sector seeks sustainable solutions to food security challenges, the role of genetic engineering through CRISPR technology becomes increasingly crucial.

Disease Models:

CRISPR technology is being widely adopted for creating disease models that mimic human diseases, facilitating research and the development of potential therapies. These models enable researchers to investigate disease mechanisms and gauge the effectiveness of new treatment approaches in a controlled environment. The increasing prevalence of complex diseases, such as cancer and neurodegenerative disorders, drives the demand for efficient disease modeling techniques. By providing accurate representations of human diseases, CRISPR-based models are becoming indispensable in drug discovery and testing, ultimately expediting the path to clinical solutions.

Functional Genomics:

Functional genomics aims to understand the relationship between gene function and phenotype, and CRISPR technology is instrumental in achieving this goal. Through precise targeted gene editing, researchers can elucidate the roles of specific genes in biological pathways and disease processes. The growing interest in understanding gene interactions and their implications in various fields, such as oncology and microbiology, continues to fuel the demand for functional genomics applications. With ongoing advancements in CRISPR methodologies and their expanding scope, functional genomics stands poised for significant growth in the coming years.

Agricultural Biotechnology:

Agricultural biotechnology is one of the most impactful applications of CRISPR technology, addressing pressing issues such as food security and crop resilience. CRISPR-enabled genetic modifications allow for the development of crops with enhanced traits, such as improved resistance to pests, diseases, and environmental stressors. The rising global population and the need for sustainable agricultural practices are driving the adoption of CRISPR technology in this sector. As researchers explore the potential of CRISPR in creating genetically modified organisms that can thrive in changing climates and meet the demands of a growing populace, the agricultural biotechnology application of CRISPR is expected to gain momentum.

By Distribution Channel

Biotechnology & Pharmaceutical Companies:

Biotechnology and pharmaceutical companies are the primary distribution channels for CRISPR products, significantly influencing market dynamics. These companies invest heavily in CRISPR research and development to create innovative solutions for genetic disorders and various diseases. Their extensive distribution networks allow for the efficient delivery of CRISPR products to researchers and clinicians. As the demand for CRISPR-based therapies and tools continues to rise, these companies are well-positioned to capitalize on the growing market, driving advancements that will enhance the efficacy and accessibility of gene-editing technologies.

Research Institutes:

Research institutes play a critical role in the CRISPR and CRISPR-associated genes market, serving as hubs for innovation and discovery. These institutions conduct in-depth research on CRISPR technology, exploring new applications and enhancing existing methodologies. The collaboration between research institutes and industry players fosters a dynamic exchange of knowledge and resources, ultimately driving advancements in CRISPR applications. As the scientific community recognizes the potential of CRISPR for transformative research, the involvement of research institutes is expected to continue growing, facilitating the development of cutting-edge solutions across various fields.

Academic Institutes:

Academic institutes are increasingly adopting CRISPR technology for educational and research purposes. They provide a platform for students and researchers to gain hands-on experience with gene-editing techniques, making them essential players in the CRISPR market. The focus on integrating CRISPR into curricula is fostering a new generation of scientists equipped with the skills to harness this technology for research and therapeutic applications. Furthermore, collaborations between academic institutions and biotech companies enhance the application of CRISPR in real-world scenarios, thus contributing to the market's expansion.

Contract Research Organizations:

Contract research organizations (CROs) are pivotal in the CRISPR market, offering specialized services to biotech and pharmaceutical companies. These organizations provide expertise in gene editing, functional genomics, and preclinical development, allowing clients to leverage advanced CRISPR technologies without the need for extensive in-house capabilities. As the demand for CRISPR-based research and development increases, CROs are well-positioned to facilitate timely and cost-effective solutions for their clients. Their involvement not only streamlines the research process but also enhances the overall efficiency of drug development pipelines.

Hospitals & Clinics:

Hospitals and clinics represent an emerging distribution channel for CRISPR technologies, particularly as gene therapies become more mainstream. As medical professionals seek to integrate cutting-edge treatments into patient care, the adoption of CRISPR-based therapies is gaining traction. Hospitals and clinics are increasingly collaborating with biotech companies to offer advanced CRISPR solutions for treating genetic disorders. The shift towards personalized medicine underscores the importance of CRISPR in clinical settings, and as more therapies receive regulatory approval, the role of hospitals and clinics in the CRISPR market will continue to expand.

By Ingredient Type

Cas9:

Cas9 is one of the most widely utilized CRISPR-associated enzymes and serves as a critical component in gene-editing applications. Its ability to target specific DNA sequences has made it a cornerstone in genome engineering, allowing researchers to create precise genetic modifications in a variety of organisms. The popularity of Cas9 is driven by its proven efficacy and versatility in various applications, including disease modeling and functional genomics. Researchers are continually exploring new Cas9 variants with enhanced properties, further propelling its demand in the market.

Cas12:

Cas12 offers distinct advantages over Cas9, such as a simpler and more efficient targeting mechanism, which has led to its increasing adoption in genetic engineering. Known for its enhanced specificity and reduced off-target effects, Cas12 is gaining favor among researchers who require high precision in gene-editing projects. As advancements continue to enhance its capabilities, the demand for Cas12 in various applications, from agriculture to personalized medicine, is expected to grow significantly. Its unique properties position Cas12 as a highly sought-after enzyme in the CRISPR landscape.

Cas13:

Cas13 is a unique CRISPR-associated enzyme primarily known for its RNA-targeting abilities, which distinguishes it from other Cas proteins that generally target DNA. This characteristic makes Cas13 particularly valuable in applications related to RNA interference and viral gene editing. With the rising focus on combating RNA viruses and understanding RNA biology, Cas13 is poised for substantial growth in the market. Researchers are increasingly exploring its potential for therapeutic applications, which is expected to drive further demand for this innovative enzyme.

Cas14:

Cas14 is a newer addition to the CRISPR enzyme family, and its potential is still being unveiled. Initial studies suggest that Cas14 can target a wider range of sequences than its predecessors, offering exciting possibilities for novel applications in gene editing. As researchers continue to investigate its unique properties and capabilities, the demand for Cas14 is likely to rise within the CRISPR market. Its potential for diverse applications—ranging from functional genomics to therapeutic interventions—positions Cas14 as a promising avenue for future exploration in CRISPR technologies.

Cpf1:

Cpf1, also known as Cas12b, is another CRISPR-associated enzyme that has garnered attention for its unique properties and applications. Cpf1 systems offer distinct advantages, such as generating sticky ends rather than blunt ends after cutting DNA, facilitating the insertion of foreign DNA. This attribute enhances the efficiency of gene editing and promotes more successful integration of new genetic material. The ongoing research into Cpf1's capabilities is expected to drive demand within the market, as it offers researchers a powerful tool for precise genetic modifications and advanced genome engineering.

By Region

The CRISPR and CRISPR-associated genes market is experiencing significant regional growth, with North America leading the charge. The North American region is anticipated to account for approximately 45% of the global market share by 2035, primarily driven by the high concentration of biotech firms and research institutions engaging in CRISPR research. Significant funding from both public and private sectors supports innovation and commercialization efforts, establishing North America as a hub for CRISPR technology development. The increasing prevalence of genetic disorders and the rising demand for personalized medicine further bolster the market in this region, contributing to a projected CAGR of around 24% during the forecast period.

Europe is another key player in the CRISPR market, accounting for around 30% of the global share. The region's focus on research and development, coupled with robust healthcare systems and regulatory frameworks, facilitates the adoption of CRISPR technologies. Countries like Germany, the UK, and France are leading the way in CRISPR-related research, advancing gene-editing applications in both healthcare and agriculture. The European market is expected to maintain a steady growth trajectory, driven by collaborations between academic institutions and biotech companies, as well as increasing public awareness of gene editing's potential benefits.

Opportunities

The CRISPR and CRISPR-associated genes market offers numerous opportunities for growth and innovation across various sectors. One of the most significant opportunities lies in the field of therapeutic applications, particularly in developing gene therapies for genetic disorders and cancers. As the scientific community continues to deepen its understanding of various diseases at the genomic level, CRISPR technology can be harnessed to create targeted treatments that address the root causes of these conditions rather than merely managing symptoms. This paradigm shift towards precision medicine opens new avenues for research and commercialization, encouraging biotech companies to invest heavily in CRISPR-based therapies. Additionally, as regulatory frameworks evolve and more therapies receive approval, the market is expected to witness a surge in demand for CRISPR applications in clinical settings.

Another promising area for growth is agricultural biotechnology, where CRISPR technology can play a transformative role in enhancing crop resilience and productivity. With the challenges posed by climate change, pests, and diseases, the demand for sustainable agricultural practices is more crucial than ever. CRISPR-enabled modifications can lead to the development of crops that require fewer resources while delivering higher yields. This potential aligns with global goals to achieve food security and sustainable farming practices. Investment in research and development in agricultural biotech using CRISPR will likely create exciting opportunities for innovation, collaboration, and commercialization, making it a vital area of focus for stakeholders in the CRISPR market.

Threats

While the CRISPR and CRISPR-associated genes market is poised for significant growth, it is not without its challenges and threats. One of the primary threats is the ethical and regulatory concerns surrounding gene editing, particularly when it comes to human applications. As CRISPR technology allows for the alteration of the human genome, issues related to its ethical implications, potential misuse, and long-term consequences are at the forefront of discussions among policymakers and the scientific community. The lack of universally accepted guidelines and regulations may hinder the pace of innovation and commercialization in the sector, as companies may face legal hurdles or public backlash, potentially stalling their research efforts and market entry.

Another considerable threat lies in the competitive landscape, as numerous players in the biotech sector are racing to develop novel applications for CRISPR technology. This intensifying competition can lead to market saturation, driving down prices and potentially affecting profit margins for companies. Additionally, the fast-paced nature of technological advancements means that companies must continuously innovate to stay relevant. Failure to keep up with rapidly changing market dynamics or to adapt to new scientific discoveries could result in reduced market share and overall growth potential. As the landscape evolves, companies must remain agile, responsive, and committed to addressing emerging challenges to thrive in the CRISPR market.

Competitor Outlook

• CRISPR Therapeutics AG
• Intellia Therapeutics, Inc.
• Editas Medicine, Inc.
• Caribou Biosciences, Inc.
• MilliporeSigma
• Thermo Fisher Scientific
• Integrated DNA Technologies (IDT)
• Horizon Discovery Group plc
• Agilent Technologies, Inc.
• Takara Bio Inc.
• Ginkgo Bioworks Inc.
• Scientific Protein Laboratories
• Synlogic, Inc.
• Lonza Group AG
• Cas9 Therapeutics, Inc.

The competitive landscape of the CRISPR and CRISPR-associated genes market is characterized by an evolving array of players, all vying for market share in this rapidly advancing field. Major companies like CRISPR Therapeutics AG and Intellia Therapeutics, Inc. are leading the way in developing innovative gene-editing therapies, with a strong focus on securing partnerships and collaborations to enhance their research capabilities. These companies are not only focusing on therapeutic applications but are also investing in expanding their CRISPR product offerings, including kits, enzymes, and systems. Their substantial investments in research and development aim to drive technological advancements that will further solidify their positions in the market.

Moreover, companies like Editas Medicine, Inc. and Caribou Biosciences, Inc. are making significant strides in advancing their CRISPR technologies, with a keen interest in exploring novel applications and ensuring regulatory compliance. The competitive dynamics are further intensified by the presence of established players such as Thermo Fisher Scientific and Agilent Technologies, which provide essential reagents and tools to researchers in the biotechnology sector. Their extensive product portfolios and distribution networks enhance their influence in the CRISPR market, making them critical competitors in the space.

The landscape is continually evolving, as smaller biotech firms and academic institutions engage in research that may yield groundbreaking discoveries. Companies like Synlogic, Inc. and Ginkgo Bioworks Inc. are exploring unique applications of CRISPR technology, potentially disrupting established norms and offering fresh solutions to complex challenges in genetic engineering. With continuous advancements in CRISPR, the competitive landscape remains dynamic, requiring all players to stay ahead of technological innovations while navigating ethical considerations and regulatory environments.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Lonza Group AG
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 MilliporeSigma
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Synlogic, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Takara Bio Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Ginkgo Bioworks Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Editas Medicine, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 CRISPR Therapeutics AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Cas9 Therapeutics, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Thermo Fisher Scientific
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Caribou Biosciences, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Agilent Technologies, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Horizon Discovery Group plc
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Intellia Therapeutics, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Scientific Protein Laboratories
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Integrated DNA Technologies (IDT)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 CRISPR And CRISPR Associated Genes Market, By Application
    • 6.1.1 Genome Engineering
    • 6.1.2 Genetic Engineering
    • 6.1.3 Disease Models
    • 6.1.4 Functional Genomics
    • 6.1.5 Agricultural Biotechnology
  • 6.2 CRISPR And CRISPR Associated Genes Market, By Ingredient Type
    • 6.2.1 Cas9
    • 6.2.2 Cas12
    • 6.2.3 Cas13
    • 6.2.4 Cas14
    • 6.2.5 Cpf1
  • 6.3 CRISPR And CRISPR Associated Genes Market, By Distribution Channel
    • 6.3.1 Biotechnology & Pharmaceutical Companies
    • 6.3.2 Research Institutes
    • 6.3.3 Academic Institutes
    • 6.3.4 Contract Research Organizations
    • 6.3.5 Hospitals & Clinics

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 CRISPR And CRISPR Associated Genes Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global CRISPR And CRISPR Associated Genes market is categorized based on

By Application

• Genome Engineering
• Genetic Engineering
• Disease Models
• Functional Genomics
• Agricultural Biotechnology

By Distribution Channel

• Biotechnology & Pharmaceutical Companies
• Research Institutes
• Academic Institutes
• Contract Research Organizations
• Hospitals & Clinics

By Ingredient Type

• Cas9
• Cas12
• Cas13
• Cas14
• Cpf1

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• CRISPR Therapeutics AG
• Intellia Therapeutics, Inc.
• Editas Medicine, Inc.
• Caribou Biosciences, Inc.
• MilliporeSigma
• Thermo Fisher Scientific
• Integrated DNA Technologies (IDT)
• Horizon Discovery Group plc
• Agilent Technologies, Inc.
• Takara Bio Inc.
• Ginkgo Bioworks Inc.
• Scientific Protein Laboratories
• Synlogic, Inc.
• Lonza Group AG
• Cas9 Therapeutics, Inc.